Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for QIAGEN N.V. (QGEN : NYSE)

• Company Description    QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia. Number of Employees: 5,765

• Price / Volume Information    Yesterday's Closing Price: $47.95 Daily Weekly Monthly 20 Day Moving Average: 941,410 shares Shares Outstanding: 222.29 (millions) Market Capitalization: $10,658.85 (millions) Beta: 0.66 52 Week High: $51.88 52 Week Low: $37.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.32% 4.17% 12 Week -4.00% -12.25% Year To Date 4.69% -10.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL HULSTERWEG 82 - PL VENLO,P7 5912 NLD ph: 31-77-355-6600 fax: 31-77-355-6658 john.gilardi@qiagen.com http://www.qiagen.com

• General Corporate Information    Officers Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Toralf Haag - Supervisory Director Eva Pisa - Supervisory Director Metin Colpan - Supervisory Director Peer Information QIAGEN N.V. (CORR.) QIAGEN N.V. (RSPI) QIAGEN N.V. (CGXP) QIAGEN N.V. (BGEN) QIAGEN N.V. (GTBP) QIAGEN N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N72482206 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 222.29 Most Recent Split Date: 1.00 (0.97:1) Beta: 0.66 Market Capitalization: $10,658.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.52% Current Fiscal Quarter EPS Consensus Estimate: $0.60 Indicated Annual Dividend: $0.25 Current Fiscal Year EPS Consensus Estimate: $2.34 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 8.15% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: 20.53 Trailing 12 Months: 20.44 PEG Ratio: 2.52 Price Ratios Price/Book: 3.04 Price/Cash Flow: 14.96 Price / Sales: 5.22 EPS Growth vs. Year Ago Period: 6.06% vs. Previous Quarter: 9.09% Sales Growth vs. Year Ago Period: 7.49% vs. Previous Quarter: 10.36% ROE 09/30/25 - - 06/30/25 - 14.77 03/31/25 - 14.61 ROA 09/30/25 - - 06/30/25 - 8.87 03/31/25 - 8.80 Current Ratio 09/30/25 - - 06/30/25 - 1.61 03/31/25 - 3.37 Quick Ratio 09/30/25 - - 06/30/25 - 1.35 03/31/25 - 2.83 Operating Margin 09/30/25 - - 06/30/25 - 25.35 03/31/25 - 25.36 Net Margin 09/30/25 - - 06/30/25 - 18.30 03/31/25 - 4.68 Pre-Tax Margin 09/30/25 - - 06/30/25 - 23.95 03/31/25 - 6.91 Book Value 09/30/25 - - 06/30/25 - 15.77 03/31/25 - 15.33 Inventory Turnover 09/30/25 - - 06/30/25 - 2.57 03/31/25 - 3.38 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.25 03/31/25 - 0.40 Debt-to-Capital 09/30/25 - - 06/30/25 - 20.15 03/31/25 - 28.41

Powered by Zacks Investment Research ©